Iambic Therapeutics Jumps 17% After-Hours as Wall Street Turns Bullish on Its AI-Powered Drug Discovery Platform

Iambic Therapeutics, Inc. (NASDAQ: IAM) shares jumped 16.82% to $15.63 in after-hours trading on Monday after Wall Street Analysts started coverage of the clinical-stage life sciences and technology company with bullish views.

Wall Street Analysts Initiate Coverage on Iambic With Buy Ratings

BofA Securities, the investment banking and research division of Bank of America, initiated coverage on Iambic Therapeutics with a Buy rating and a $30 price target on Monday.

The firm highlighted Iambic’s use of proprietary AI models combined with automated chemistry to design cancer drugs. According to the analyst, this approach could shorten drug development timelines and reduce costs, Investing.com reported.

Bank of America also noted that Iambic uses AI to design new molecules rather than focusing on identifying disease targets, distinguishing its approach from other AI-driven drug developers.

Jefferies subsequently initiated coverage on Iambic with a Buy rating and a $35 price target on Monday, according to a report by Investing.com.

The firm highlighted the potential of Iambic’s AI platform to scale and offset research and development costs. Jefferies also pointed to early data from IAM1363, a HER2 tyrosine kinase inhibitor, showing encouraging activity in heavily pretreated patients with HER2-positive breast cancer brain metastases. However, the firm noted that its superiority over newer HER2 tyrosine kinase inhibitors remains unproven.

Iambic to Participate in Jefferies Global Healthcare Conference

Iambic announced Monday that its Co-Founder and CEO, Tom Miller, will attend the Jefferies Global Healthcare Conference, scheduled for November 16-19 in London. Miller will participate in a panel discussion on AI in drug discovery on Nov. 18 at 2:00 p.m. GMT.

The conference is in its 17th year and brings together leaders from the pharmaceutical, biotechnology, healthcare and health technology industries.

Miller said the opportunity for AI in drug discovery lies in integrating insights across chemistry, biology and clinical development to improve the probability of developing successful medicines.

Iambic Advances AI-Driven Drug Discovery Platform

Iambic’s platform, which the company calls molecular superintelligence, integrates proprietary AI technologies with automated chemistry and biology experimentation.

The company said its technology has supported the discovery of IAM1363, a drug candidate that advanced to clinical development in approximately two years. Iambic also has a preclinical pipeline and develops AI technologies including Enchant and NeuralPLexer, designed to improve drug discovery and clinical development.

Trading Metrics, Technical Analysis

Iambic Therapeutics has a market capitalization of about $634.22 million.

Iambic shares have traded between a 52-week high of $25 and a 52-week low of $9.60.

Over the past 12 months, Iambic Therapeutics shares have declined 29.24%.

Price Action: Iambic Therapeutics shares gained 31.56% to close at $13.38 during Monday’s regular trading session.

Image via Shutterstock